Intended for healthcare professionals

Letters Screening for hepatitis C

Authors’ reply to Foster and colleagues

BMJ 2015; 350 doi: (Published 24 February 2015) Cite this as: BMJ 2015;350:h1000
  1. Ronald L Koretz, emeritus professor of clinical medicine1,
  2. Kenneth W Lin, associate professor of family medicine2,
  3. John P A Ioannidis, professor of medicine3,
  4. Jeanne Lenzer, medical investigative journalist4
  1. 1David Geffen-UCLA School of Medicine, CA, USA
  2. 2Georgetown University School of Medicine, Washington, DC, USA
  3. 3Stanford University, CA, USA
  4. 4New York, USA
  1. jeanne.lenzer{at}

We thank Foster and colleagues for their comments.1 2 Projections of disease progression that are based on natural history studies from tertiary referral centres may exaggerate hepatitis C virus (HCV) related morbidity and mortality. Inception cohort and epidemiological data suggest that only a minority of infected people will progress to end stage liver disease over their lifetime.1

Foster and colleagues repeatedly asserted that treatment is effective, but the cited evidence cannot show this.3 4 5 Van der Meer summarised …

View Full Text

Log in

Log in through your institution


* For online subscription